CzechiaTuberculosis profile
Population  2015 11 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.039 (0.039–0.039) 0.37 (0.37–0.37)
Mortality (HIV+TB only) <0.01 (0–<0.01) 0.01 (0–0.04)
Incidence  (includes HIV+TB) 0.55 (0.47–0.63) 5.2 (4.4–6)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.06 (0.04–0.07)
Incidence (MDR/RR-TB)** 0.015 (<0.01–0.026) 0.14 (0.04–0.25)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.014 (<0.01–0.023) 0.16 (0.098–0.22) 0.17 (0.1–0.24)
Males 0.022 (0.014–0.029) 0.35 (0.28–0.43) 0.37 (0.29–0.45)
Total 0.036 (0.026–0.046) 0.51 (0.46–0.55) 0.55 (0.47–0.63)
TB case notifications, 2015  
Total cases notified 518
Total new and relapse 508
          - % tested with rapid diagnostics at time of diagnosis 46%
          - % with known HIV status 36%
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 93% (81–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.07 (0.06–0.09)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 2 1%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  13
(3–22)
Estimated % of TB cases with MDR/RR-TB 1.7% (0.56–4) 13% (1.7–40)  
% notified tested for rifampicin resistance 73% 64% 372
MDR/RR-TB cases tested for resistance to second-line drugs   8
Laboratory-confirmed cases MDR/RR-TB: 10, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: 10, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 76% 467
Previously treated cases, excluding relapse, registered in 2014 65% 37
HIV-positive TB cases, all types, registered in 2014 0% 1
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data